Evidence map›Paper›PMID 41333208›Full record

ArticleFrontiers in oncology2025

Aberrant sialic acid metabolism promotes metabolic reprogramming and metastasis in breast cancer.

Longyu Yang, Zhenhua Li, Meijin Wang, Xing Xiong, Shilin Zhang, Zhi Man, Chunyan Dong, Li Fu

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Longyu Yang *Shanghai Clinical Research and Trial Center, ShanghaiTech University, Shanghai, China.
Zhenhua Li *Shanghai Clinical Research and Trial Center, ShanghaiTech University, Shanghai, China.
Meijin WangShanghai Clinical Research and Trial Center, ShanghaiTech University, Shanghai, China.
Xing XiongShanghai Clinical Research and Trial Center, ShanghaiTech University, Shanghai, China.
Shilin ZhangShanghai Clinical Research and Trial Center, ShanghaiTech University, Shanghai, China.
Zhi ManShanghai Clinical Research and Trial Center, ShanghaiTech University, Shanghai, China.
Chunyan DongDepartment of Oncology, East Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, China.
Li FuShanghai Clinical Research and Trial Center, ShanghaiTech University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dysregulated tumour metabolism is increasingly recognised as a central driver of malignant phenotypes. Against this background, the aberrant metabolism of N-acetylneuraminic acid (Neu5Ac), a core constituent of the sialic acid family, and its impact on breast cancer progression is now receiving significant research attention. Methods: The purpose of this study is to employ metabolomic approaches to analyze and interpret differences in metabolite profiles connected to breast cancer. Following this, a comprehensive multi-omics analysis will be employed to reveal the differences at transcriptional and metabolic levels in cells after the addition of external sialic acid. Finally, modification proteomics will be applied to recognize and characterize proteins that have different sialylation patterns. Results: Cells treated with sialic acid showed improved motility, underwent metabolic reprogramming, and experienced a significant rise in the sialylation levels of key proteins. Conclusion: This study collectively elucidates the role of Neu5Ac metabolism in promoting breast cancer invasion and metastasis through the remodeling of lipid metabolic pathways and alterations in protein sialylation. The findings present novel evidence supporting the targeting of sialic acid metabolism and its modifications as potential therapeutic strategies for inhibiting tumor progression.

Indexed as

breast cancermetabolic reprogrammingmetastasisNeu5Acsialylation

Identifiers

PMID41333208
PMCPMC12665555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.